Cargando…
A Liver Model of Infantile-Onset Pompe Disease Using Patient-Specific Induced Pluripotent Stem Cells
Infantile-onset Pompe disease (IOPD) is a life-threatening multi-organ disease caused by an inborn defect of lysosomal acid α-glucosidase (GAA), which can degrade glycogen into glucose. Lack of GAA causes abnormal accumulation of glycogen in the lysosomes, particularly in the skeletal muscle, liver,...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6895003/ https://www.ncbi.nlm.nih.gov/pubmed/31850350 http://dx.doi.org/10.3389/fcell.2019.00316 |
_version_ | 1783476498653511680 |
---|---|
author | Yoshida, Takeshi Jonouchi, Tatsuya Osafune, Kenji Takita, Junko Sakurai, Hidetoshi |
author_facet | Yoshida, Takeshi Jonouchi, Tatsuya Osafune, Kenji Takita, Junko Sakurai, Hidetoshi |
author_sort | Yoshida, Takeshi |
collection | PubMed |
description | Infantile-onset Pompe disease (IOPD) is a life-threatening multi-organ disease caused by an inborn defect of lysosomal acid α-glucosidase (GAA), which can degrade glycogen into glucose. Lack of GAA causes abnormal accumulation of glycogen in the lysosomes, particularly in the skeletal muscle, liver, and heart. Enzyme replacement therapy (ERT) with recombinant human GAA (rhGAA) is the only available treatment; however, its effect varies by organ. Thus, to fully understand the pathomechanism of IOPD, organ-specific disease models are necessary. We previously generated induced pluripotent stem cells (iPSCs) from three unrelated patients with IOPD and establish a skeletal muscle model of IOPD. Here, we used the same iPSC lines as the previous study and differentiated them into hepatocytes. As a result, hepatocytes differentiated from iPSC of IOPD patients showed abnormal accumulation of lysosomal glycogen, the hallmark of Pompe disease. Using this model, we also demonstrated that glycogen accumulation was dose-dependently restored by rhGAA treatment. In conclusion, we have successfully established an in vitro liver model of IOPD using patient-specific iPSCs. This model can be a platform to elucidate the underlying disease mechanism or to be applied to drug-screening. Moreover, our study also suggest that an iPSC-based approach is suitable for modeling of diseases that affect multiple organs like Pompe disease. |
format | Online Article Text |
id | pubmed-6895003 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-68950032019-12-17 A Liver Model of Infantile-Onset Pompe Disease Using Patient-Specific Induced Pluripotent Stem Cells Yoshida, Takeshi Jonouchi, Tatsuya Osafune, Kenji Takita, Junko Sakurai, Hidetoshi Front Cell Dev Biol Cell and Developmental Biology Infantile-onset Pompe disease (IOPD) is a life-threatening multi-organ disease caused by an inborn defect of lysosomal acid α-glucosidase (GAA), which can degrade glycogen into glucose. Lack of GAA causes abnormal accumulation of glycogen in the lysosomes, particularly in the skeletal muscle, liver, and heart. Enzyme replacement therapy (ERT) with recombinant human GAA (rhGAA) is the only available treatment; however, its effect varies by organ. Thus, to fully understand the pathomechanism of IOPD, organ-specific disease models are necessary. We previously generated induced pluripotent stem cells (iPSCs) from three unrelated patients with IOPD and establish a skeletal muscle model of IOPD. Here, we used the same iPSC lines as the previous study and differentiated them into hepatocytes. As a result, hepatocytes differentiated from iPSC of IOPD patients showed abnormal accumulation of lysosomal glycogen, the hallmark of Pompe disease. Using this model, we also demonstrated that glycogen accumulation was dose-dependently restored by rhGAA treatment. In conclusion, we have successfully established an in vitro liver model of IOPD using patient-specific iPSCs. This model can be a platform to elucidate the underlying disease mechanism or to be applied to drug-screening. Moreover, our study also suggest that an iPSC-based approach is suitable for modeling of diseases that affect multiple organs like Pompe disease. Frontiers Media S.A. 2019-11-29 /pmc/articles/PMC6895003/ /pubmed/31850350 http://dx.doi.org/10.3389/fcell.2019.00316 Text en Copyright © 2019 Yoshida, Jonouchi, Osafune, Takita and Sakurai. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cell and Developmental Biology Yoshida, Takeshi Jonouchi, Tatsuya Osafune, Kenji Takita, Junko Sakurai, Hidetoshi A Liver Model of Infantile-Onset Pompe Disease Using Patient-Specific Induced Pluripotent Stem Cells |
title | A Liver Model of Infantile-Onset Pompe Disease Using Patient-Specific Induced Pluripotent Stem Cells |
title_full | A Liver Model of Infantile-Onset Pompe Disease Using Patient-Specific Induced Pluripotent Stem Cells |
title_fullStr | A Liver Model of Infantile-Onset Pompe Disease Using Patient-Specific Induced Pluripotent Stem Cells |
title_full_unstemmed | A Liver Model of Infantile-Onset Pompe Disease Using Patient-Specific Induced Pluripotent Stem Cells |
title_short | A Liver Model of Infantile-Onset Pompe Disease Using Patient-Specific Induced Pluripotent Stem Cells |
title_sort | liver model of infantile-onset pompe disease using patient-specific induced pluripotent stem cells |
topic | Cell and Developmental Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6895003/ https://www.ncbi.nlm.nih.gov/pubmed/31850350 http://dx.doi.org/10.3389/fcell.2019.00316 |
work_keys_str_mv | AT yoshidatakeshi alivermodelofinfantileonsetpompediseaseusingpatientspecificinducedpluripotentstemcells AT jonouchitatsuya alivermodelofinfantileonsetpompediseaseusingpatientspecificinducedpluripotentstemcells AT osafunekenji alivermodelofinfantileonsetpompediseaseusingpatientspecificinducedpluripotentstemcells AT takitajunko alivermodelofinfantileonsetpompediseaseusingpatientspecificinducedpluripotentstemcells AT sakuraihidetoshi alivermodelofinfantileonsetpompediseaseusingpatientspecificinducedpluripotentstemcells AT yoshidatakeshi livermodelofinfantileonsetpompediseaseusingpatientspecificinducedpluripotentstemcells AT jonouchitatsuya livermodelofinfantileonsetpompediseaseusingpatientspecificinducedpluripotentstemcells AT osafunekenji livermodelofinfantileonsetpompediseaseusingpatientspecificinducedpluripotentstemcells AT takitajunko livermodelofinfantileonsetpompediseaseusingpatientspecificinducedpluripotentstemcells AT sakuraihidetoshi livermodelofinfantileonsetpompediseaseusingpatientspecificinducedpluripotentstemcells |